118 related articles for article (PubMed ID: 38561039)
1. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
[TBL] [Abstract][Full Text] [Related]
2. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
3. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3
Wang X; Lang M; Zhao T; Feng X; Zheng C; Huang C; Hao J; Dong J; Luo L; Li X; Lan C; Yu W; Yu M; Yang S; Ren H
Oncogene; 2017 May; 36(21):3048-3058. PubMed ID: 27991933
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
5. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY
Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
[TBL] [Abstract][Full Text] [Related]
7. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas.
Luo X; Yang Z; Liu X; Liu Z; Miao X; Li D; Zou Q; Yuan Y
Tumour Biol; 2017 May; 39(5):1010428317699129. PubMed ID: 28466777
[TBL] [Abstract][Full Text] [Related]
10. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma.
Venkat S; Tisdale AA; Schwarz JR; Alahmari AA; Maurer HC; Olive KP; Eng KH; Feigin ME
Genome Res; 2020 Mar; 30(3):347-360. PubMed ID: 32029502
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Masugi Y; Yamazaki K; Emoto K; Effendi K; Tsujikawa H; Kitago M; Itano O; Kitagawa Y; Sakamoto M
Lab Invest; 2015 Mar; 95(3):308-19. PubMed ID: 25599535
[TBL] [Abstract][Full Text] [Related]
12. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
14. Gli1 expression in pancreatic ductal adenocarcinoma and its clinical significance.
Abula Y; Yi C; Wang XY; Wang M; Qin RY; Guo YQ; Lin H; Li HJ
Genet Mol Res; 2015 Oct; 14(4):12323-9. PubMed ID: 26505381
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
16. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
Iakovlev V; Siegel ER; Tsao MS; Haun RS
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
[TBL] [Abstract][Full Text] [Related]
17. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.
Riener MO; Pilarsky C; Gerhardt J; Grützmann R; Fritzsche FR; Bahra M; Weichert W; Kristiansen G
Histol Histopathol; 2009 Sep; 24(9):1121-8. PubMed ID: 19609859
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]